Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* The participant has confirmed acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or 2 confirmed GAA gene mutations.~* The participant must provide signed, informed consent prior to performing any study related procedures. Consent of a legally authorized guardian(s) is (are) required for legally minor participant as defined by local regulation. If the participant is legally minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from participants, if applicable.~Exclusion criteria:~* The participant is \<3 years of age.~* The participant has known Pompe specific cardiac hypertrophy.~* The participant is wheelchair dependent.~* The participant is not able to ambulate 40 meters (approximately 130 feet) without stopping and without an assistive device.~* The participant requires invasive-ventilation (non-invasive ventilation is allowed).~* The participant is not able to successfully perform repeated forced vital capacity (FVC) measurements in upright position of greater than or equal to 30% predicted and less than or equal to 85% predicted.~* The participant (and participant's legal guardian if participant is legally minor as defined by local regulation) is (are) not able to comply with the clinical protocol.~* The participant has had previous treatment with alglucosidase alfa or any investigational therapy for Pompe disease.~* The participant has prior or current use of immune tolerance induction therapy.~* The participant, if female and of childbearing potential, has a positive pregnancy test (beta-human chorionic gonadotropin) at baseline.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- avalglucosidase alfa (GZ402666) (Type: EXPERIMENTAL): Administered intravenously every 2 weeks
- alglucosidase alfa (GZ419829) (Type: ACTIVE_COMPARATOR): Administered intravenously every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).